Digestive Diseases and Sciences

, Volume 63, Issue 11, pp 3041–3048 | Cite as

Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation?

  • Ji Young Chang
  • Jae Hee CheonEmail author
  • Yehyun Park
  • Soo Jung Park
  • Tae-Il Kim
  • Won-Ho Kim
Original Article



Discrepancies between clinical symptoms and mucosal inflammation have been reported in up to 50% of patients with ulcerative colitis (UC). However, there are no guidelines and only limited information for appropriate treatment manipulation.


We aimed to evaluate long-term outcomes according to treatment strategies and determine predictive factors for disease relapse in UC patients who are in clinical remission (CR) but still have endoscopic inflammation.


A total of 204 patients who were confirmed as achieving CR but still had mucosal inflammation were included. CR was defined as “partial Mayo score ≤ 1” with no changes in medications or use of any corticosteroids during the past 3 months. An active mucosal lesion was defined as “endoscopic Mayo subscore > 0.”


The mean patient age was 43.5 years, and 53.9% were male. The mean disease duration was 89.9 months. During a mean follow-up of 34 months, 90 patients (44%) experienced disease relapse. The cumulative relapse-free rate did not differ by treatment strategy (maintenance of current therapy vs. dose elevation or step-up therapy). Multivariate analysis revealed that left-side colitis or pancolitis at diagnosis (OR 2.10; 95% CI 1.04–4.27; P = 0.040) and number of extraintestinal manifestations ≥ 2 (OR 5.62; 95% CI 1.10–28.68; P = 0.038) were independent predictive factors for disease relapse.


The current medical acceleration treatment strategy did not have a significant influence on the long-term outcomes of UC patients in CR but with active mucosal inflammation. Disease extent at diagnosis and extraintestinal manifestations were independently predictive of disease relapse.


Ulcerative colitis Clinical remission Relapse Mucosal inflammation 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

10620_2018_5193_MOESM1_ESM.docx (15 kb)
Supplementary material 1 (DOCX 14 kb)


  1. 1.
    Cintolo M, Costantino G, Pallio S, Fries W. Mucosal healing in inflammatory bowel disease: maintain or de-escalate therapy. World J Gastrointest Pathophysiol. 2016;7:1–16.CrossRefGoogle Scholar
  2. 2.
    Dignass A, Lindsay JO, Sturm A, Windsor A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991–1030.CrossRefGoogle Scholar
  3. 3.
    Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, et al. Results from the 2nd Scientific Workshop of the ECCO (I): impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011;5:477–483.CrossRefGoogle Scholar
  4. 4.
    Walsh A, Palmer R, Travis S. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. Gastrointest Endosc Clin N Am. 2014;24:367–378.CrossRefGoogle Scholar
  5. 5.
    Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813–1816.CrossRefGoogle Scholar
  6. 6.
    Frøslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412–422.CrossRefGoogle Scholar
  7. 7.
    Reinink AR, Lee TC, Higgins PD. Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: a meta-analysis. Inflamm Bowel Dis. 2016;22:1859–1869.CrossRefGoogle Scholar
  8. 8.
    Baars JE, Nuij VJ, Oldenburg B, Kuipers EJ, van der Woude CJ. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis. 2012;18:1634–1640.CrossRefGoogle Scholar
  9. 9.
    Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut. 2014;63:88–95.CrossRefGoogle Scholar
  10. 10.
    Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.CrossRefGoogle Scholar
  11. 11.
    Lee YJ, Cheon JH, Kim JH, Yoo S, et al. Clinical efficacy of beclomethasone dipropionate in Korean patients with ulcerative colitis. Yonsei Med J. 2017;58:144–149.CrossRefGoogle Scholar
  12. 12.
    Dai C, Liu W-X, Jiang M, Sun M-J. Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy. PLoS ONE. 2014;9:e110797.CrossRefGoogle Scholar
  13. 13.
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317:1625–1629.CrossRefGoogle Scholar
  14. 14.
    Kim JH, Cheon JH, Park Y, Lee HJ, et al. Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission. Scand J Gastroenterol. 2016;51:1069–1074.CrossRefGoogle Scholar
  15. 15.
    D’Haens G, Sandborn WJ, Feagan BG, Geboes K, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–786.CrossRefGoogle Scholar
  16. 16.
    Nakarai A, Kato J, Hiraoka S, Inokuchi T, et al. Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count. World J Gastroenterol. 2014;20:18367–18374.CrossRefGoogle Scholar
  17. 17.
    Christensen B, Hanauer SB, Erlich J, Kassim O, et al. Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes. Clin Gastroenterol Hepatol. 2017;15:1557–1564.e1551.CrossRefGoogle Scholar
  18. 18.
    Bryant RV, Burger DC, Delo J, Walsh AJ, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65:408–414.CrossRefGoogle Scholar
  19. 19.
    Colombel JF, Rutgeerts P, Reinisch W, Esser D, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–1201.CrossRefGoogle Scholar
  20. 20.
    Rosenberg L, Lawlor GO, Zenlea T, Goldsmith JD, et al. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission: endoscopic colitis despite clinical remission. Inflamm Bowel Dis. 2013;19:779–784.CrossRefGoogle Scholar
  21. 21.
    Sohn IW, Kim ST, Kim B, Lee HJ, et al. Efficacy of adalimumab in Korean patients with Crohn’s disease. Gut Liver. 2016;10:255–261.CrossRefGoogle Scholar
  22. 22.
    Jung YS, Han M, Kim WH, Park S, Cheon JH. Incidence and clinical outcomes of inflammatory bowel disease in South Korea, 2011–2014: a nationwide population-based study. Dig Dis Sci. 2017;62:2102–2112.CrossRefGoogle Scholar
  23. 23.
    Travis SP, Higgins PD, Orchard T, Van Der Woude CJ, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011;34:113–124.CrossRefGoogle Scholar
  24. 24.
    Manginot C, Baumann C, Peyrin-Biroulet L. An endoscopic Mayo score of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis. Gut. 2015;64:1181–1182.CrossRefGoogle Scholar
  25. 25.
    Lee HJ, Jung ES, Lee JH, Hong SP, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis. Hepato-gastroenterology. 2012;59:1415–1420.PubMedGoogle Scholar
  26. 26.
    Solberg IC, Lygren I, Jahnsen J, Aadland E, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431–440.CrossRefGoogle Scholar
  27. 27.
    Hoie O, Wolters FL, Riis L, Bernklev T, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507–515.CrossRefGoogle Scholar
  28. 28.
    Duricova D, Leroyer A, Savoye G, Sarter H, et al. Extra-intestinal manifestations at diagnosis in paediatric- and elderly-onset ulcerative colitis are associated with a more severe disease outcome: a population-based study. J Crohns Colitis. 2017;11:1326–1334.CrossRefGoogle Scholar
  29. 29.
    Lakatos L, Pandur T, David G, Balogh Z, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003;9:2300–2307.CrossRefGoogle Scholar
  30. 30.
    Vavricka SR, Brun L, Ballabeni P, Pittet V, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110–119.CrossRefGoogle Scholar
  31. 31.
    Isene R, Bernklev T, Høie O, Munkholm P, et al. Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scand J Gastroenterol. 2015;50:300–305.CrossRefGoogle Scholar
  32. 32.
    Vegh Z, Kurti Z, Gonczi L, Golovics PA, et al. Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease. Scand J Gastroenterol. 2016;51:848–854.CrossRefGoogle Scholar
  33. 33.
    Leo S, Leandro G, Di Matteo G, Caruso ML, Lorusso D. Ulcerative colitis in remission: it is possible to predict the risk of relapse? Digestion. 1989;44:217–221.CrossRefGoogle Scholar
  34. 34.
    Rinawi F, Zevit N, Eliakim R, Niv Y, Shamir R, Assa A. Long-term outcomes after primary bowel resection in pediatric-onset Crohn’s disease. Inflamm Bowel Dis. 2017;24:149–158.CrossRefGoogle Scholar
  35. 35.
    Billson FA, De Dombal FT, Watkinson G, Goligher JC. Ocular complications of ulcerative colitis. Gut. 1967;8:102–106.CrossRefGoogle Scholar
  36. 36.
    Naganuma M, Sakuraba A, Hibi T. Ulcerative colitis: prevention of relapse. Expert Rev Gastroenterol Hepatol. 2013;7:341–351.CrossRefGoogle Scholar
  37. 37.
    Plevy SE, Targan SR. Future therapeutic approaches for inflammatory bowel diseases. Gastroenterology. 2011;140:1838–1846.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Ji Young Chang
    • 1
  • Jae Hee Cheon
    • 1
    Email author
  • Yehyun Park
    • 1
  • Soo Jung Park
    • 1
  • Tae-Il Kim
    • 1
  • Won-Ho Kim
    • 1
  1. 1.Department of Internal Medicine and Institute of GastroenterologyYonsei University College of MedicineSeoulRepublic of Korea

Personalised recommendations